22 Results for "

permeability transition pore inhibitor

" in MedChemExpress (MCE) Product Catalog:
Products (22)

22 Results for "permeability transition pore inhibitor" in MCE Product Catalog:

905
905 Publications Verification
Cat. No.: HY-15763
CAS No.: 571203-78-6
Purity:  99.62%
Research Areas:  

Cancer

Erastin is a ferroptosis inducer. Erastin exhibits the mechanism of ferroptosis induction related to ROS and iron-dependent signaling. Erastin inhibits voltage-dependent anion channels (VDAC2/VDAC3) and accelerates oxidation, leading to the accumulation of endogenous reactive oxygen species. Erastin also disrupts mitochondrial permeability transition pore (mPTP) with anti-tumor activity. Furthermore, Erastin can block the uptake of cystine mediated by SLC7A11 and also spares UMRC6-EV and -C91A cells from disulfidptosis under glucose starvation .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-100852
CAS No.: 792957-74-5
Purity:  ≥98.0%
Research Areas:  

Cancer

ER-000444793 is a potent inhibitor of mitochondrial permeability transition pore (mPTP) opening. ER-000444793 inhibits mPTP with an IC50 of 2.8 μM.
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-131370B
CAS No.: 68890-65-3
Synonyms: 20% Fat Emulsion
Intralipid 20% is a safe fat emulsion, composed of soybean oil (consisting of a mixture of long-chain triglycerides (C14-24) of predominantly unsaturated fatty acids), and egg phospholipids, can be used as a nutritional supplement. Intralipid 20% effectively inhibits the opening of the mitochondrial permeability transition pore, effectively protecting the heart from ischaemia-reperfusion injury and has some potential to modulate the innate immune response .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-N0237
CAS No.: 126054-77-1
Atractyloside A is an orally active inhibitor of the TLR4/MyD88/NF-κB signaling pathway and also an opener of the mitochondrial permeability transition pore (MPTP). Atractyloside A interferes with the activation of the TLR4/MyD88/NF-κB pathway, thereby inhibiting intestinal inflammatory responses. Atractyloside A reverses mucin synthesis impairment, improves intestinal barrier integrity, and restores homeostasis by altering the composition of the gut microbiota. Atractyloside A can be used in studies related to spleen deficiency diarrhea and myocardial injury .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N4280
CAS No.: 2445-80-9
7,8-Dimethoxycoumarin is a coumarin compound derived from Artemisia caruifolia with oral activity. 7,8-Dimethoxycoumarin inhibits mitochondrial permeability transition pore and H +/K +-ATPase, and exhibits antioxidant, anti-inflammatory, renoprotective, neuroprotective and gastroprotective effects. 7,8-Dimethoxycoumarin reduces lipid peroxidation (TBARS), increases GSH levels, inhibits myeloperoxidase (MPO) activity, and regulates the expression of inflammatory factors by inhibiting the NF‑κB and MAPK pathways. 7,8-Dimethoxycoumarin ameliorates gastric mucosal injury, alleviates renal tissue lesions and relieves neuropathic pain. 7,8-Dimethoxycoumarin can be used in studies related to acute renal failure, trigeminal neuralgia and gastritis .
loading...
    loading...
Cat. No.: HY-175715
CAS No.: 3077720-24-9
Research Areas:  

Neurological Disease

NRG1271 is an orally active mitochondrial permeability transition pore (mPTP) inhibitor with blood-brain barrier penetration. NRG1271 can be used for the study of Neurological Disease .
loading...
    loading...
Cat. No.: HY-N0663
CAS No.: 20501-56-8
Talatisamine is an orally active cyclophilin D activator isolated from the roots of Aconitum carmichaeli Debx. Talatisamine exerts biological functions by activating cyclophilin D, inhibiting Ca 2+-dependent opening of the mitochondrial permeability transition pore (mPTP) (IC50=78 μM), and blocking delayed rectifier K + channels (IC50=146 μM). Talatisamine possesses both antioxidant and membrane-stabilizing properties, effectively inhibits lipid peroxidation and protects mitochondrial membrane function. Talatisamine exhibits multiple activities including antiarrhythmic, hypotensive, anti-inflammatory, anticancer and neuroprotective effects. Talatisamine finds applications in the research of ischemic diseases, rheumatoid arthritis, inflammation-related diseases and Alzheimer's disease .
loading...
    loading...
Cat. No.: HY-119909
CAS No.: 1223568-82-8
Purity:  98.09%
Research Areas:  

Cardiovascular Disease

GNX-865 is a mitochondrial permeability transition pore (mPTP) inhibitor that protects against ischemia-reperfusion injury in vivo .
loading...
    loading...
Cat. No.: HY-112715
CAS No.: 1023043-30-2
Purity:  99.56%
Target:  

ATP Synthase

Research Areas:  

Cardiovascular Disease

ATP synthase inhibitor 1 is a potent inhibitor of c subunit of the F1/FO-ATP synthase complex, inhibits mitochondrial permeability transition pore (mPTP) opening, does not affect ATP levels .
loading...
    loading...
Cat. No.: HY-108984
CAS No.: 97120-13-3
Synonyms: 5-(Benzylsulfonyl)-4-bromo-2-methyl-3(2H)-pyridazinone
Research Areas:  

Neurological Disease

BBMP is a permeability transition pore (PTP) inhibitor. BBMP prevents Ca 2+-induced permeability transition and mitochondrial depolarization. BBMP possess potential for the neurodegenerative disorders research .
loading...
    loading...
Cat. No.: HY-172959
CAS No.: 554414-59-4
Research Areas:  

Cardiovascular Disease

mPTP-IN-1 (Compound 14e) is a mitochondrial permeability transition pore (mPTP) inhibitor. mPTP-IN-1 blocks calcium-induced mPTP opening by targeting the C subunit of ATP synthase. mPTP-IN-1 can be used to study myocardial ischemia/reperfusion injury (IRI) .
loading...
    loading...
Cat. No.: HY-172227
CAS No.: 148089-70-7
Research Areas:  

Cardiovascular Disease

S-15176 is an inhibitor of the mitochondrial permeability transition pore (PTP). S-15176 inhibits mitochondrial swelling induced by tert-butylhydroperoxide with an IC50 value of 45.7 μM. S-15176 inhibits PTP opening, prevents mitochondrial membrane potential dissipation and NAD(P)H oxidation, and increases mitochondrial calcium loading capacity. S-15176 is promising for research of ischemia-reperfusion injury .
loading...
    loading...
Cat. No.: HY-114898
CAS No.: 1826026-00-9
ML404 (Compound 38) is an inhibitor of the mitochondrial permeability transition pore (mtPTP), which can suppress mitochondrial swelling (EC50=4.9 nM) and only disrupts mitochondrial coupling (an adverse effect) at concentrations > 100 μM. ML404 can be utilized in research related to multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), muscular dystrophies (MD), myocardial infarction, and stroke .
loading...
    loading...
Cat. No.: HY-136804
CAS No.: 1115335-95-9
Target:  

Cyclophilin

Research Areas:  

Neurological Disease

CypD-IN-29 (compound 29) is an inhibitor of the Alzheimer's disease target CypD (KD=88.2 nM). CypD is a mitochondrial-specific cyclophilin that can bind to β-amyloid protein in brain mitochondria and promote the formation of mitochondrial permeability transition pore (mPTP).
loading...
    loading...
Cat. No.: HY-101999
CAS No.: 141266-44-6
Research Areas:  

Cancer

EM20-25 is an inhibitor for Bcl-2, which interferes with the interaction between BCL-2 and BAX, activates caspase-9 and thus induces the apoptosis. EM20-25 affects the mitochondrial function, causes the open of permeability transition pore (PTP). EM20-25 enhances the sensitivity of cells to Staurosporine (HY-15141), and enhances the killing effect of BCL-2-expressing leukemia cells to Chlorambucil (HY-13593) and Fludarabine (HY-B0069) .
loading...
    loading...
Cat. No.: HY-179417
Target:  

Cyclophilin

Research Areas:  

Inflammation/Immunology

CypD-IN-7 is a potent cyclophilin D (CypD/PPIF) inhibitor that inhibits CypD PPIase activity (K i = 2.4 nM) and provides protection against mitochondrial permeability transition pore (MPTP) opening. CypD-IN-7 can be used for pancreatitis research .
loading...
    loading...
Cat. No.: HY-179416
Target:  

Cyclophilin

Research Areas:  

Inflammation/Immunology

CypD-IN-6 is a potent cyclophilin D (CypD/PPIF) inhibitor that inhibits CypD PPIase activity (Ki = 32 nM) and binds to CypD (Kd = 60 nM). CypD-IN-6 can be used for mitochondrial permeability transition pore (MPTP) related disease research such as ischemia-reperfusion injury and acute pancreatitis 1.
loading...
    loading...
Cat. No.: HY-100852R
CAS No.: 792957-74-5
Research Areas:  

Cancer

ER-000444793 (Standard) is the analytical standard of ER-000444793 (HY-100852). This product is intended for research and analytical applications. ER-000444793 is a potent inhibitor of mitochondrial permeability transition pore (mPTP) opening. ER-000444793 inhibits mPTP with an IC50 of 2.8 μM.
loading...
    loading...
Cat. No.: HY-W223348
CAS No.: 759424-59-4
Org-9768 (Compound (2-methyl-2,3-dihydro-1H-inden-2-yl)methanamine) is a drug intermediate for synthesizing the mitochondrial permeability transition pore (mPTP) inhibitor. Org-9768 can be used for the researches of neurological and cardiovascular disease, such as Parkinson's disease .
loading...
    loading...
Cat. No.: HY-P11489
CAS No.: 252731-57-0
RN-0001 is a cyclophilin (Cyp) inhibitor with Ki values of 4.1 nM and 12.0 nM against CypA and CypD, respectively, and an EC50 of 916 nM for CypD. RN-0001 binds directly to CypD, inhibits the peptidyl-prolyl cis-trans isomerase activities of CypD and CypA, and prevents CypD-dependent mitochondrial permeability transition pore opening. RN-0001 improves mitochondrial function, reduces ROS production, inhibits the expression of lipogenic markers, blocks the nuclear translocation of NF-κB p65, and decreases the release of activated caspase-3 and cytochrome c. RN-0001 can be used in the research of alcohol-associated liver disease .
loading...
    loading...